Nodom Combi (Dorzolamide Hydrochloride, Timolol Maleate)

Dorzolamide Hydrochloride and Timolol Maleate, the active ingredients in Nodom Combi, are a carbonic anhydrase inhibitor and a beta‑adrenergic antagonist presented as a 2% w/v Dorzolamide / 0.5% w/v Timolol ophthalmic solution for ocular (topical) use. The combination reduces intra‑ocular pressure and is indicated for primary open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Nodom Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance, regulatory compliance and reliable global logistics.

Nodom Combi, a combination antiglaucoma ophthalmic solution, is used to manage conditions that involve elevated intra‑ocular pressure.

Primary open‑angle glaucoma: lowers intra‑ocular pressure to prevent optic nerve damage. Ocular hypertension: reduces pressure to decrease risk of progression to glaucoma. Other forms of glaucoma where pressure reduction is required: provides adjunctive therapy when monotherapy is insufficient.

Nodom Combi may cause ocular and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Blurred vision: transient visual disturbance after instillation. - Eye irritation or burning: mild discomfort at the application site. - Altered taste: bitter taste sensation after drainage through nasolacrimal duct. - Headache: mild to moderate headache reported by some users.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Stevens‑Johnson syndrome: rare but potentially life‑threatening skin reaction. - Significant bradycardia: unusually slow heart rate requiring medical attention. - Hypotension: marked drop in blood pressure, especially in susceptible patients.

Before prescribing Nodom Combi, clinicians should consider several safety measures.

Assess intra‑ocular pressure before initiating therapy: baseline measurement guides effectiveness. Monitor for signs of bronchospasm in patients with asthma or COPD: beta‑blocker component may exacerbate. Check cardiac function in patients with bradycardia or heart block: timolol can lower heart rate. Avoid concurrent use with other carbonic anhydrase inhibitors: additive effect may cause excessive pressure reduction. Store at room temperature: keep in original container, protect from light and moisture.

Nodom Combi can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers: may cause additive bradycardia and hypotension. - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): risk of excessive reduction of aqueous humor. - Other ocular hypotensive agents used without physician guidance: may lead to uncontrolled intra‑ocular pressure changes.

Moderate Interactions (Monitor Closely): - Topical anesthetics: may increase corneal toxicity when used together. - Systemic antihypertensives: monitor blood pressure for additive lowering effect. - Respiratory bronchodilators: may reduce efficacy of timolol, requiring pulmonary function monitoring.